Frontiers in Pharmacology · 2023 · 11 citations · 22 references
MedicineOncologyUrologyGenitourinary OncologyProstate DiseaseUrologic OncologyAndrogen Deprivation TherapyGenitourinary Cancer PharmacotherapyHormonal Cancer TherapyHormonal TherapyProstate CancerAdjuvant Androgen Deprivation TherapyAdvanced Prostate Cancer TherapyNeoadjuvant Androgen Deprivation TherapyNeoadjuvant Hormonal TherapyNeoadjuvant Therapy TrialsPhase Ii Clinical TrialsPhase Ii Oncology TrialsProstate Cancer Hormonal Therapy
Objective: The study aimed to compare the efficacy and safety of androgen deprivation therapy (ADT) with abiraterone or docetaxel versus ADT alone as neoadjuvant therapy in patients with very-high-risk localized prostate cancer. Methods: This was a pooled analysis of two single-center, randomized, controlled, phase II clinical trials ( ClinicalTrials.gov : NCT04356430 and NCT04869371) conducted from December 2018 to March 2021. Eligible participants were randomly assigned to the intervention (ADT plus abiraterone or docetaxel) and control (ADT alone) groups at a 2:1 ratio. Efficacy was evaluated by pathological complete response (pCR), minimal residual disease (MRD), and 3-year biochemical progression-free survival (bPFS). Safety was also analyzed. Results: The study included 42 participants in the ADT group, 47 in the ADT plus docetaxel group, and 48 in the ADT plus abiraterone group. A total of 132 (96.4%) participants had very-high-risk prostate cancer, and 108 (78.8%) had locally advanced disease. The ADT plus docetaxel group (28%) and ADT plus abiraterone group (31%) had higher rates of pCR or MRD ( p = 0.001 and p < 0.001) compared with the ADT group (2%). The 3-year bPFS was 41.9% (95% CI: 26.6–57.2), 51.1% (95% CI: 36.8–65.4), and 61.2% (95% CI: 45.5–76.9), respectively. Significant difference was found among groups in terms of bPFS ( p = 0.037). Conclusion: Compared with ADT alone, neoadjuvant therapy with ADT plus docetaxel or abiraterone could achieve better pathological outcomes (pCR or MRD) for very-high-risk localized prostate cancer. The ADT plus abiraterone group showed longer bPFS than ADT alone. The combination regimens were tolerable.
22
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi, NamPhuong Tran, Luis Fein et al. · New England Journal of Medicine · 2017 · 2.2K citations · Full text
Medicine, Oncology, Pharmacotherapy +15
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
Nicholas D. James, Johann S. de Bono, Melissa Spears et al. · New England Journal of Medicine · 2017 · 1.8K citations · Full text
Andrew J. Armstrong, Russell Z. Szmulewitz, Daniel P. Petrylak et al. · Journal of Clinical Oncology · 2019 · 1.2K citations · Full text
Medicine, Oncology, Pharmacotherapy +17